G. Simonneau (Clamart, France), A. Peacock (Glasgow, United Kingdom)
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
R. Barst, B. Brundage, A. Ghofrani, R. Oudiz, G. Simonneau, A. Beardsworth, M. Chan, N. Galie (New York, NY, Bend, OR, Torrance, CA, United States Of America; Giessen, Germany; Clamart, France; Erl Wood, United Kingdom; Danforth, Canada; Bologna, Italy)
|  |
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
H. Leuchte, C. Baezner, R. Baumgartner, C. Neurohr, D. Bevec, G. Bacher, J. Behr (Munich, Germany; Basel, Switzerland)
| |
Ambrisentan therapy for PAH patients with WHO class II symptoms: one year follow-up.
A. Ghofrani, D. Richards, T. Hutchinson, C. Dufton, On Behalf of the ARIES Study Group (Giessen, Germany; Harlow, Essex, United Kingdom; Westminster, CO, United States Of America)
| |
Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan
M. Hoeper, N. Galie, L. Rubin, P. Jansa, A. Kusic-Pajic, G. Simonneau (Hannover, Germany; Bologna, Italy; La Jolla, United States Of America; Prague, Czech Republic; Allschwil, Switzerland; Clamart, France)
|  |
Exercise training in pulmonary hypertension improves muscle efficiency and exercise capacity
F. S. de Man, H. Groepenhoff, M. L. Handoko, A. van ‘t Hul, J. Abbink, H. P. Grotjohan, H. Konter, R. J. H. Koppers, A. Boonstra, N. Westerhof, P. E. Postmus, W. J. van der Laarse, A. Vonk-Noordegraaf (Amsterdam, Breda, Leiden, Zwolle, Enschede, Leeu
| |
Effect of exercise and respiratory training on time to clinical worsening and survival in patients with severe chronic pulmonary hypertension
A. Krill, N. Ehlken, H. Wenz, A. Ghofrani, G. Staehler, M. Halank, R. Ewert, A. Meyer, H. Wilkens, M. M. Hoeper, F. J. Meyer, G. Karger, J. Buss, J. Juenger, C. Opitz, H. J. Seyfarth, F. F. J. Herth, H. Klose, H. Bremer, J. Mayer, H. Wilkend, S. Rosenkran
| |
Acetazolamide, chronic mountain sickness and pulmonary hypertension
J. P. Richalet, M. Maignan, M. Rivera-Ch, I. Pham, F. Leon-Velarde (Bobigny, France; Lima, Peru)
|  |
Experimental treatments for interventricular dyssynchrony in pulmonary hypertension can be investigated in the MCT-rat model
M. L. Handoko, R. R. Lamberts, E. M. Redout, J. W. Lankhaar, F. S. de Man, C. Boer, W. J. Paulus, C. P. Allaart, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
| |